Last Updated: November 16, 2026

Beone Medicines Usa Company Profile

« Back to Dashboard


What is the competitive landscape for BEONE MEDICINES USA

BEONE MEDICINES USA has three approved drugs.

There are fourteen US patents protecting BEONE MEDICINES USA drugs.

Summary for Beone Medicines Usa
US Patents:14
Tradenames:2
Ingredients:2
NDAs:3

Drugs and US Patents for Beone Medicines Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Beone Medicines Usa BRUKINSA zanubrutinib TABLET;ORAL 218785-001 Jun 10, 2025 RX Yes Yes 12,233,069 ⤷  Start Trial Y ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No 11,896,596 ⤷  Start Trial ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib TABLET;ORAL 218785-001 Jun 10, 2025 RX Yes Yes 11,786,531 ⤷  Start Trial ⤷  Start Trial
Beone Medicines Usa BEQALZI sonrotoclax TABLET;ORAL 220711-001 May 13, 2026 RX Yes No 11,420,968 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Beone Medicines Usa Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2989106 SPC/GB22/006 United Kingdom ⤷  Start Trial PRODUCT NAME: ZANUBRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/21/1576 (NI) 20211122; UK FURTHER MA ON IPSUM 20211122
2989106 C202230011 Spain ⤷  Start Trial PRODUCT NAME: ZANUBRUTINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF AUTHORISATION: 20211122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1576; DATE OF FIRST AUTHORISATION IN EEA: 20211122
2989106 LUC00250 Luxembourg ⤷  Start Trial PRODUCT NAME: ZANUBRUTINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1576 20211123
2989106 4/2022 Austria ⤷  Start Trial PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 (MITTEILUNG) 20211123
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.